Prolonged adjuvant capecitabine chemotherapy improved survival of stage IIIA gastric cancer after D2 gastrectomy - 08/06/15
, Hui Hui Guo, Ying Bao, Mao Yun FeiBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Goals |
This study aims to investigate the safety and efficacy of prolonged adjuvant capecitabine chemotherapy on survival of gastric cancer after D2 gastrectomy.
Background |
Inadequate evidence is available on optimal duration of chemotherapy and the number of administered cycles is generally based on patient responsiveness and individual tolerability as well as physician preferences.
Study |
We randomly assigned 307 gastric cancer patients after D2 gastrectomy between January 2006 and December 2010 to XELOX group and Prolonged group. XELOX consisted of a 2-h intravenous infusion of oxaliplatin 130mg/mg on day 1 and oral capecitabine 1000mg/m2 twice daily on days 1–14 of a 3-week cycle for eight cycles in half a year. In Prolonged group, patients underwent extra oral capecitabine 1000mg/m2 twice daily on days 1–14 of a 3-week cycle for eight cycles after eight cycles of XELOX. The disease-free survival and overall survival were compared.
Results |
Significant differences were found in 3-year disease-free survival (Prolonged group 56.6%, XELOX group 48.4%, P=0.0357). Subgroup analysis by TNM staging showed that patients with stage IIIA gastric cancer in the Prolonged group had significantly higher DFS (50.00% vs 40.96, P=0.0178) and OS (71.95% vs 57.83, P=0.0230) than that of patients in the XELOX group. No grade 4 adverse effects or treatment-related deaths were reported. More patients in the Prolonged group experienced hand-foot syndrome than in the XELOX group.
Conclusions |
Prolonged capecitabine chemotherapy prevents improves the prognosis of patients with stage IIIA gastric cancer after D2 gastrectomy.
Le texte complet de cet article est disponible en PDF.Keywords : Gastric cancer, D2 gastrectomy, Recurrence, Chemotherapy
Plan
Vol 72
P. 140-143 - mai 2015 Retour au numéro
Article précédent
- Sirtuin-4 (SIRT4) is downregulated and associated with some clinicopathological features in gastric adenocarcinoma
- Guoyu Huang, Feifei Cui, Fudong Yu, Huijun Lu, Meng Zhang, Huamei Tang, Zhihai Peng
- Self-assembled betulinic acid protects doxorubicin induced apoptosis followed by reduction of ROS–TNF-?–caspase-3 activity
- Sandeep Kumar Dash, Sourav Chattopadhyay, Totan Ghosh, Shib Shankar Dash, Satyajit Tripathy, Balaram Das, Braja Gopal Bag, Debasis Das, Somenath Roy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?